Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Verve Therapeutics Inc (NQ: VERV )

6.150 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 6.150
Bid (Size) 5.970 (3)
Ask (Size) 6.200 (21)
Prev. Close 6.150
Today's Range 6.150 - 6.150
52wk Range 5.840 - 21.42
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga

Performance

YTD
-56.07%
-56.07%
1 Month
-26.08%
-26.08%
3 Month
-45.14%
-45.14%
6 Month
-55.85%
-55.85%
1 Year
-61.92%
-61.92%

More News

Read More
After a Serious Setback, Is Verve Therapeutics a Buy?
Via The Motley Fool
Cathie Wood's Ark Invest Sheds $6.4M Worth Of Coinbase Shares Despite Positive Market Movements, Analyst Upgrade
Via Benzinga
Cathie Wood's Ark Invest Buys More Shares Of This Meta Platforms Competitor
Via Benzinga
Verve Therapeutics: Q4 Earnings Insights
Via Benzinga
Nasdaq Down Over 1%; VivoPower International Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
Dow Stumbles, Heads For Worst Day Since February
Via Talk Markets
Topics Stocks
Exposures US Equities
Why Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Gene Therapy Side Effects: Verve Therapeutics Halts Enrollment Of Lead Gene Therapy Trial In Patients With Bad Cholesterol
Via Benzinga
Crude Oil Surges Over 1%; US Factory Orders Increase In February
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
From Schall Law
Via GlobeNewswire
Verve Plummets To Record Low After Its Gene-Editing Drug Causes Side Effects
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Verve Therapeutics Announces Updates on its PCSK9 Program
From Verve Therapeutics
Via GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
3 Stocks That Could Be the Next Big Thing in Gene Editing
Via InvestorPlace
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug
Via Investor's Business Daily
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
From Verve Therapeutics
Via GlobeNewswire
3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough Potential
Via InvestorPlace
3 Gene Editing Stocks With Unprecedented Surge Potential
Via InvestorPlace
2 Risky Gene-Editing Stocks to Buy in the New Bull Market if You Dare
Via The Motley Fool
Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Verve Therapeutics
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.